Table 4.
EC50 and Hill slope parameters determined for selected inhibitors using 1f:DcpS, 2g:DcpS, 2h:DcpS, and 2i:DcpS systems.
| Ligand | 1f :DcpS | 2g:DcpS | 2h:DcpS | 2i:DcpS | ||||
|---|---|---|---|---|---|---|---|---|
| EC50 ± SD (nM) | Hill slope | EC50 ± SD (nM) | Hill slope | EC50 ± SD (nM) | Hill slope | EC50 ± SD (nM) | Hill slope | |
| m7GMP | 104 ± 11 | 1.19 ± 0.15 | 112 ± 11 | 1.04 ± 0.02 | 357 ± 44 | 0.93 ± 0.07 | 255 ± 14 | 1.00 ± 0.02 |
| m7GDP | 36.5 ± 3.6 | 1.98 ± 0.18 | 16.4 ± 0.2 | 1.55 ± 0.09 | 31.2 ± 10.7 | 1.06 ± 0.37 | 36.2 ± 4.7 | 1.42 ± 0.06 |
| m7GpNHppG | 27.8 ± 2.7 | 2.26 ± 0.16 | 11.6 ± 0.4 | 1.95 ± 0.07 | 18.1 ± 5.0 | 1.23 ± 0.44 | 17.9 ± 1.3 | 1.66 ± 0.10 |
| RG3039 | 48.5 ± 3.7 | 3.03 ± 1.51 | 15.4 ± 2.7 | 3.52 ± 1.06 | 6.1 ± 0.6 | 7.66 ± 2.19 | 10.0 ± 2.0 | 3.67 ± 0.51 |